• Jacques Corcos
  • Mikolaj Przydacz


  • In neurological patients, retention may result from neurogenic detrusor underactivity (NDU) or detrusor-sphincter dyssynergia (DSD).

  • Comprehensive history and physical examination must be completed by means of a bladder/catheterization diary, questionnaires, urinalysis, urine culture, uroflowmetry, post-void residual measurement, urinary tract ultrasound, and other optional investigations. Urodynamic study is the cornerstone in the diagnosis, allowing clinicians to distinguish between NDU and DSD.

  • Treatment of retention aims to protect renal function and should involve intermittent catheterization or suprapubic catheter in all patients with a high post-void residual. Indwelling catheterization should be avoided, as it may lead to multiple complications.

  • Management also includes sacral neuromodulation, intrasphincteric injections of botulinum toxin A, and surgery. Nevertheless, currently available supportive data are sparse.


Retention Neurogenic detrusor underactivity Detrusor-sphincter dyssynergia Intermittent catheterization Clean intermittent catheterization Sterile intermittent catheterization Indwelling catheterization Suprapubic tube Sacral neuromodulation Intrasphincteric injections of botulinum toxin A External sphincterotomy 


  1. 1.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Chapple CR, Osman NI, Birder L, van Koeveringe GA, Oelke M, Nitti VW, et al. The underactive bladder: a new clinical concept? Eur Urol. 2015;68(3):351–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Li X, Liao L. Updates of underactive bladder: a review of the recent literature. Int Urol Nephrol. 2016;48(6):919–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith PP, Birder LA, Abrams P, Wein AJ, Chapple CR. Detrusor underactivity and the underactive bladder: symptoms, function, cause-what do we mean? ICI-RS think tank 2014. Neurourol Urodyn. 2016;35(2):312–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Kadow BT, Tyagi P, Chermansky CJ. Neurogenic causes of detrusor underactivity. Curr Bladder Dysfunct Rep. 2015;10(4):325–31.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Liu Z, Uchiyama T, Sakakibara R, Yamamoto T. Underactive and overactive bladders are related to motor function and quality of life in Parkinson’s disease. Int Urol Nephrol. 2015;47(5):751–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Castro-Diaz D, Taracena Lafuente JM. Detrusor-sphincter dyssynergia. Int J Clin Pract Suppl. 2006;151:17–21.CrossRefGoogle Scholar
  8. 8.
    De EJ, Patel CY, Tharian B, Westney OL, Graves DE, Hairston JC. Diagnostic discordance of electromyography (EMG) versus voiding cystourethrogram (VCUG) for detrusor-external sphincter dyssynergy (DESD). Neurourol Urodyn. 2005;24(7):616–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Bacsu CD, Chan L, Tse V. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int. 2012;109(Suppl 3):31–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Weld KJ, Graney MJ, Dmochowski RR. Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury. Urology. 2000;56(4):565–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77(5):643–50.PubMedGoogle Scholar
  12. 12.
    Staiman VR, Lowe FC. Urologic problems in patients with acquired immunodeficiency syndrome. Sci World J. 2004;4(Suppl 1):427–37.CrossRefGoogle Scholar
  13. 13.
    Gyrtrup HJ, Kristiansen VB, Zachariae CO, Krogsgaard K, Colstrup H, Jensen KM. Voiding problems in patients with HIV infection and AIDS. Scand J Urol Nephrol. 1995;29(3):295–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zeman A, Donaghy M. Acute infection with human immunodeficiency virus presenting with neurogenic urinary retention. Genitourin Med. 1991;67(4):345–7.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Menendez V, Valls J, Espuna M, Perez A, Barranco MA, Carretero P. Neurogenic bladder in patients with acquired immunodeficiency syndrome. Neurourol Urodyn. 1995;14(3):253–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Hermieu JF, Delmas V, Boccon-Gibod L. Micturition disturbances and human immunodeficiency virus infection. J Urol. 1996;156(1):157–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Mahfouz W, Corcos J. Management of detrusor external sphincter dyssynergia in neurogenic bladder. Eur J Phys Rehabil Med. 2011;47(4):639–50.PubMedGoogle Scholar
  18. 18.
    Rivas DA, Chancellor MB. Neurogenic vesical dysfunction. Urol Clin North Am. 1995;22(3):579–91.PubMedGoogle Scholar
  19. 19.
    Onal B, Siva A, Buldu I, Demirkesen O, Cetinel B. Voiding dysfunction due to multiple sclerosis: a large scale retrospective analysis. Int Braz J Urol. 2009;35(3):326–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161(3):743–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Aggarwal H, Zimmern PE. Underactive bladder. Curr Urol Rep. 2016;17(3):17.PubMedCrossRefGoogle Scholar
  22. 22.
    Malik RD, Cohn JA, Bales GT. Urinary retention in elderly women: diagnosis & management. Curr Urol Rep. 2014;15(11):454.PubMedCrossRefGoogle Scholar
  23. 23.
    Tyagi P, Smith PP, Kuchel GA, de Groat WC, Birder LA, Chermansky CJ, et al. Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol. 2014;46(Suppl 1):S11–21.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Bromage SJ, Dorkin TJ, Chan L, Tse V. Urodynamics in the octogenarian female: is it worthwhile? Int Urogynecol J. 2010;21(9):1117–21.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeong SJ, Kim HJ, Lee YJ, Lee JK, Lee BK, Choo YM, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53(5):342–8.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Cameron AP, Rodriguez GM, Gursky A, He C, Clemens JQ, Stoffel JT. The severity of bowel dysfunction in patients with neurogenic bladder. J Urol. 2015;194(5):1336–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Vodusek DB. Lower urinary tract and sexual dysfunction in neurological patients. Eur Neurol. 2014;72(1–2):109–15.PubMedCrossRefGoogle Scholar
  28. 28.
    European Association of Urology (EAU). Non-oncology guidelines. Neuro-urology. 2016. Accessed 16 May 2017.
  29. 29.
    Rosenstein D, McAninch JW. Urologic emergencies. Med Clin North Am. 2004;88(2):495–518.PubMedCrossRefGoogle Scholar
  30. 30.
    Curtis LA, Dolan TS, Cespedes RD. Acute urinary retention and urinary incontinence. Emerg Med Clin North Am. 2001;19(3):591–619.PubMedCrossRefGoogle Scholar
  31. 31.
    Fuselier HA Jr. Etiology and management of acute urinary retention. Compr Ther. 1993;19(1):31–6.PubMedGoogle Scholar
  32. 32.
    Bacsu C, Lemack GE. Clinical evaluation: history and physical examination. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 337–47.Google Scholar
  33. 33.
    Verhamme KM, Dieleman JP, Van Wijk MA, van der Lei J, Bosch JL, Stricker BH, et al. Nonsteroidal anti-inflammatory drugs and increased risk of acute urinary retention. Arch Intern Med. 2005;165(13):1547–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Dorflinger A, Monga A. Voiding dysfunction. Curr Opin Obstet Gynecol. 2001;13(5):507–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Young M, Rovner E. The voiding diary. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 347–50.Google Scholar
  37. 37.
    Berman P, Hogan DB, Fox RA. The atypical presentation of infection in old age. Age Ageing. 1987;16(4):201–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Yoshikawa TT. Unique aspects of urinary tract infection in the geriatric population. Gerontology. 1984;30(5):339–44.PubMedCrossRefGoogle Scholar
  39. 39.
    National Institute for Health and Care Excellence (NICE), National Clinical Guideline Centre [Internet]. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease; 2012 [Cited: 2017 February].
  40. 40.
    Storme OA, McCammon KA. Noninvasive urodynamics. In: Peterson AC, Fraser MO, editors. Practical urodynamics for the clinician. Cham: Springer; 2016. p. 31–41.CrossRefGoogle Scholar
  41. 41.
    Frimodt-Moller C. Diabetic cystopathy. A review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan Med Bull. 1978;25(2):49–60.PubMedGoogle Scholar
  42. 42.
    Drake MJ. Management and rehabilitation of neurologic patients with lower urinary tract dysfunction. Handb Clin Neurol. 2015;130:451–68.PubMedCrossRefGoogle Scholar
  43. 43.
    Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720–32.PubMedCrossRefGoogle Scholar
  44. 44.
    Wyndaele JJ. The management of neurogenic lower urinary tract dysfunction after spinal cord injury. Nat Rev Urol. 2016;13(12):705–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–7.PubMedGoogle Scholar
  46. 46.
    Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65(2):389–98.PubMedCrossRefGoogle Scholar
  47. 47.
    Goode PS, Locher JL, Bryant RL, Roth DL, Burgio KL. Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(5):296–300.PubMedCrossRefGoogle Scholar
  48. 48.
    Griffiths DJ, Harrison G, Moore K, McCracken P. Variability of post-void residual urine volume in the elderly. Urol Res. 1996;24(1):23–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Marks LS, Dorey FJ, Macairan ML, Park C, deKernion JB. Three-dimensional ultrasound device for rapid determination of bladder volume. Urology. 1997;50(3):341–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Nygaard IE. Postvoid residual volume cannot be accurately estimated by bimanual examination. Int Urogynecol J Pelvic Floor Dysfunct. 1996;7(2):74–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Ouslander JG, Simmons S, Tuico E, Nigam JG, Fingold S, Bates-Jensen B, et al. Use of a portable ultrasound device to measure post-void residual volume among incontinent nursing home residents. J Am Geriatr Soc. 1994;42(11):1189–92.PubMedCrossRefGoogle Scholar
  52. 52.
    Rosier PF, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International Continence Society Good Urodynamic Practices and Terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2016;36(5):1243–60.PubMedCrossRefGoogle Scholar
  53. 53.
    Winters JC, Dmochowski RR, Goldman HB, Herndon CD, Kobashi KC, Kraus SR, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464–72.PubMedCrossRefGoogle Scholar
  54. 54.
    Drake MJ, Williams J, Bijos DA. Voiding dysfunction due to detrusor underactivity: an overview. Nat Rev Urol. 2014;11(8):454–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Bacsu C, Hou JC, Lemack GE. Bladder emptying: contractility. In: Rovner ES, Koski ME, editors. Rapid and practical interpretation of urodynamics. New York: Springer; 2015. p. 227–49.Google Scholar
  56. 56.
    Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84(1):14–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Griffiths CJ, Harding C, Blake C, McIntosh S, Drinnan MJ, Robson WA, et al. A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol. 2005;174(4 Pt 1):1323–6. Discussion 6; Author reply 6PubMedCrossRefGoogle Scholar
  58. 58.
    Schafer W. Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: from complex to simple. World J Urol. 1995;13(1):47–58.PubMedCrossRefGoogle Scholar
  59. 59.
    Tan TL, Bergmann MA, Griffiths D, Resnick NM. Stop test or pressure-flow study? Measuring detrusor contractility in older females. Neurourol Urodyn. 2004;23(3):184–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Rovner ES, Koski ME, editors. Rapid and practical interpretation of urodynamics. New York: Springer; 2015.Google Scholar
  61. 61.
    Peterson AC, Fraser MO, editors. Practical urodynamics for the clinician. Cham: Springer; 2016.Google Scholar
  62. 62.
    Wyndaele JJ. Is impaired perception of bladder filling during cystometry a sign of neuropathy? Br J Urol. 1993;71(3):270–3.PubMedCrossRefGoogle Scholar
  63. 63.
    Erdem E, Akbay E, Doruk E, Cayan S, Acar D, Ulusoy E. How reliable are bladder perceptions during cystometry? Neurourol Urodyn. 2004;23(4):306–9. Discussion 10PubMedCrossRefGoogle Scholar
  64. 64.
    De Wachter S, Van Meel TD, Wyndaele JJ. Can a faked cystometry deceive patients in their perception of filling sensations? A study on the reliability of spontaneously reported cystometric filling sensations in patients with non-neurogenic lower urinary tract dysfunction. Neurourol Urodyn. 2008;27(5):395–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Wyndaele JJ. Normality in urodynamics studied in healthy adults. J Urol. 1999;161(3):899–902.PubMedCrossRefGoogle Scholar
  66. 66.
    Smith AL, Wang MY, Wein AJ. Bladder filling and storage: “capacity”. In: Rovner ES, Koski ME, editors. Rapid and practical interpretation of urodynamics. New York: Springer; 2015. p. 155–70.Google Scholar
  67. 67.
    Harris C, Smith PP, Gousse AE. Bladder emptying: coordination of bladder and sphincters. In: Rovner ES, Koski ME, editors. Rapid and practical interpretation of urodynamics. New York: Springer; 2015. p. 251–62.Google Scholar
  68. 68.
    Borawski KM. The EMG. In: Peterson AC, Fraser MO, editors. Practical urodynamics for the clinician. Cham: Springer; 2016. p. 77–87.CrossRefGoogle Scholar
  69. 69.
    Spettel S, Kalorin C, De E. Combined diagnostic modalities improve detection of detrusor external sphincter dyssynergia. ISRN Obstet Gynecol. 2011;2011:323421.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Blaivas JG, Sinha HP, Zayed AA, Labib KB. Detrusor-external sphincter dyssynergia: a detailed electromyographic study. J Urol. 1981;125(4):545–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Yalla SV, Blunt KJ, Fam BA, Constantinople NL, Gittes RF. Detrusor-urethral sphincter dyssynergia. J Urol. 1977;118(6):1026–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Yalla SV, Yap W, Fam BA. Detrusor urethral sphincter dyssynergia: micturitional vesicourethral pressure profile patterns. J Urol. 1982;128(5):969–73.PubMedCrossRefGoogle Scholar
  73. 73.
    Karsenty G, Reitz A, Wefer B, Boy S, Schurch B. Understanding detrusor sphincter dyssynergia—significance of chronology. Urology. 2005;66(4):763–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Nitti VW, Tu LM, Gitlin J. Diagnosing bladder outlet obstruction in women. J Urol. 1999;161(5):1535–40.PubMedCrossRefGoogle Scholar
  75. 75.
    Schurch B, Schmid DM, Karsenty G, Reitz A. Can neurologic examination predict type of detrusor sphincter-dyssynergia in patients with spinal cord injury? Urology. 2005;65(2):243–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006;29(5):527–73.Google Scholar
  77. 77.
    Drake MJ, Apostolidis A, Cocci A, Emmanuel A, Gajewski JB, Harrison SC, et al. Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence Committee of the fifth international consultation on incontinence 2013. Neurourol Urodyn. 2016;35(6):657–65.PubMedCrossRefGoogle Scholar
  78. 78.
    Wyndaele JJ, Kovindha A, Madersbacher H, Radziszewski P, Ruffion A, Schurch B, et al. Neurologic urinary incontinence. Neurourol Urodyn. 2010;29(1):159–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Chartier-Kastler E, Denys P. Intermittent catheterization with hydrophilic catheters as a treatment of chronic neurogenic urinary retention. Neurourol Urodyn. 2011;30(1):21–31.PubMedCrossRefGoogle Scholar
  80. 80.
    Goldmark E, Niver B, Ginsberg DA. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15(10):448.PubMedCrossRefGoogle Scholar
  81. 81.
    Parsons BA, Narshi A, Drake MJ. Success rates for learning intermittent self-catheterisation according to age and gender. Int Urol Nephrol. 2012;44(4):1127–31.PubMedCrossRefGoogle Scholar
  82. 82.
    Oh SJ, Shin HI, Paik NJ, Yoo T, Ku JH. Depressive symptoms of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Spinal Cord. 2006;44(12):757–62.PubMedCrossRefGoogle Scholar
  83. 83.
    Perkash I, Giroux J. Clean intermittent catheterization in spinal cord injury patients: a followup study. J Urol. 1993;149(5):1068–71.PubMedCrossRefGoogle Scholar
  84. 84.
    Wilde MH, Brasch J, Zhang Y. A qualitative descriptive study of self-management issues in people with long-term intermittent urinary catheters. J Adv Nurs. 2011;67(6):1254–63.PubMedCrossRefGoogle Scholar
  85. 85.
    Bolinger R, Engberg S. Barriers, complications, adherence, and self-reported quality of life for people using clean intermittent catheterization. J Wound Ostomy Continence Nurs. 2013;40(1):83–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Woodbury MG, Hayes KC, Askes HK. Intermittent catheterization practices following spinal cord injury: a national survey. Can J Urol. 2008;15(3):4065–71.PubMedGoogle Scholar
  87. 87.
    Kovindha A, Mai WN, Madersbacher H. Reused silicone catheter for clean intermittent catheterization (CIC): is it safe for spinal cord-injured (SCI) men? Spinal Cord. 2004;42(11):638–42.PubMedCrossRefGoogle Scholar
  88. 88.
    Lapides J, Diokno AC, Lowe BS, Kalish MD. Followup on unsterile intermittent self-catheterization. J Urol. 1974;111(2):184–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Shamout S, Biardeau X, Corcos J, Campeau L. Outcome comparison of different approaches to self-intermittent catheterization in neurogenic patients: a systematic review. Spinal Cord. 2017; doi: 10.1038/sc.2016.192.
  90. 90.
    Jamison J, Maguire S, McCann J. Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders. Cochrane Database Syst Rev. 2013;11:CD004375.Google Scholar
  91. 91.
    Prieto-Fingerhut T, Banovac K, Lynne CM. A study comparing sterile and nonsterile urethral catheterization in patients with spinal cord injury. Rehabil Nurs. 1997;22(6):299–302.PubMedCrossRefGoogle Scholar
  92. 92.
    Kiddoo D, Sawatzky B, Bascu CD, Dharamsi N, Afshar K, Moore KN. Randomized crossover trial of single use hydrophilic coated vs multiple use polyvinylchloride catheters for intermittent catheterization to determine incidence of urinary infection. J Urol. 2015;194(1):174–9.PubMedCrossRefGoogle Scholar
  93. 93.
    International Continence Society (ICS), International Consultation on Incontinence (ICI), University College London, University of Southampton. Continence product advisor. Intermittent catheters. 2017. Accessed 14 May 2017.
  94. 94.
    Stensballe J, Looms D, Nielsen PN, Tvede M. Hydrophilic-coated catheters for intermittent catheterisation reduce urethral micro trauma: a prospective, randomised, participant-blinded, crossover study of three different types of catheters. Eur Urol. 2005;48(6):978–83.PubMedCrossRefGoogle Scholar
  95. 95.
    López Pereira P, Martínez Urrutia MJ, Lobato L, Rivas S, Jaureguizar Monereo E. Comparative study of the degree of patient satisfaction in intermittent catheterization with Lofric and polyvinyl chloride catheters. Actas Urol Esp. 2001;25(10):725–30. [Article in Spanish]PubMedCrossRefGoogle Scholar
  96. 96.
    Sutherland RS, Kogan BA, Baskin LS, Mevorach RA. Clean intermittent catheterization in boys using the LoFric catheter. J Urol. 1996;156(6):2041–3.PubMedCrossRefGoogle Scholar
  97. 97.
    De Ridder DJ, Everaert K, Fernandez LG, Valero JV, Duran AB, Abrisqueta ML, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol. 2005;48(6):991–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Vapnek JM, Maynard FM, Kim J. A prospective randomized trial of the LoFric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterization. J Urol. 2003;169(3):994–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Martins G, Soler ZA, Batigalia F, Moore KN. Clean intermittent catheterization: educational booklet directed to caregivers of children with neurogenic bladder dysfunction. J Wound Ostomy Continence Nurs. 2009;36(5):545–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Lindehall B, Moller A, Hjalmas K, Jodal U. Long-term intermittent catheterization: the experience of teenagers and young adults with myelomeningocele. J Urol. 1994;152(1):187–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Maynard FM, Glass J. Management of the neuropathic bladder by clean intermittent catheterisation: 5 year outcomes. Paraplegia. 1987;25(2):106–10.PubMedCrossRefGoogle Scholar
  102. 102.
    Hansen RB, Biering-Sorensen F, Kristensen JK. Bladder emptying over a period of 10-45 years after a traumatic spinal cord injury. Spinal Cord. 2004;42(11):631–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Lindehall B, Abrahamsson K, Jodal U, Olsson I, Sillen U. Complications of clean intermittent catheterization in young females with myelomeningocele: 10 to 19 years of followup. J Urol. 2007;178(3 Pt 1):1053–5.PubMedCrossRefGoogle Scholar
  104. 104.
    Bakke A, Vollset SE. Risk factors for bacteriuria and clinical urinary tract infection in patients treated with clean intermittent catheterization. J Urol. 1993;149(3):527–31.PubMedCrossRefGoogle Scholar
  105. 105.
    Tenke P, Koves B, Johansen TE. An update on prevention and treatment of catheter-associated urinary tract infections. Curr Opin Infect Dis. 2014;27(1):102–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents. 2001;17(4):299–303.PubMedCrossRefGoogle Scholar
  107. 107.
    Nickel JC, Grant SK, Costerton JW. Catheter-associated bacteriuria. An experimental study. Urology. 1985;26(4):369–75.PubMedCrossRefGoogle Scholar
  108. 108.
    Liedl B. Catheter-associated urinary tract infections. Curr Opin Urol. 2001;11(1):75–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Igawa Y, Wyndaele JJ, Nishizawa O. Catheterization: possible complications and their prevention and treatment. Int J Urol. 2008;15(6):481–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Lavelle RS, Coskun B, Bacsu CD, Gliga LA, Christie AL, Lemack GE. Quality of life after suprapubic catheter placement in patients with neurogenic bladder conditions. Neurourol Urodyn. 2016;35(7):831–5.PubMedCrossRefGoogle Scholar
  111. 111.
    Mitsui T, Minami K, Furuno T, Morita H, Koyanagi T. Is suprapubic cystostomy an optimal urinary management in high quadriplegics?. A comparative study of suprapubic cystostomy and clean intermittent catheterization. Eur Urol. 2000;38(4):434–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Ku JH, Jung TY, Lee JK, Park WH, Shim HB. Risk factors for urinary stone formation in men with spinal cord injury: a 17-year follow-up study. BJU Int. 2006;97(4):790–3.PubMedCrossRefGoogle Scholar
  113. 113.
    Nomura S, Ishido T, Teranishi J, Makiyama K. Long-term analysis of suprapubic cystostomy drainage in patients with neurogenic bladder. Urol Int. 2000;65(4):185–9.PubMedCrossRefGoogle Scholar
  114. 114.
    El Masri y WS, Patil S, Prasanna KV, Chowdhury JR. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord. 2014;52(1):49–53.PubMedCrossRefGoogle Scholar
  115. 115.
    Katsumi HK, Kalisvaart JF, Ronningen LD, Hovey RM. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord. 2010;48(4):325–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Nyman MA, Schwenk NM, Silverstein MD. Management of urinary retention: rapid versus gradual decompression and risk of complications. Mayo Clin Proc. 1997;72(10):951–6.PubMedCrossRefGoogle Scholar
  117. 117.
    Aboseif S, Tamaddon K, Chalfin S, Freedman S, Mourad MS, Chang JH, et al. Sacral neuromodulation in functional urinary retention: an effective way to restore voiding. BJU Int. 2002;90(7):662–5.PubMedCrossRefGoogle Scholar
  118. 118.
    Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, et al. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol. 2001;165(1):15–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Dasgupta R, Wiseman OJ, Kitchen N, Fowler CJ. Long-term results of sacral neuromodulation for women with urinary retention. BJU Int. 2004;94(3):335–7.PubMedCrossRefGoogle Scholar
  120. 120.
    van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, Lycklama a Nijholt AA, Siegel S, Jonas U, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178(5):2029–34.PubMedCrossRefGoogle Scholar
  121. 121.
    Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5.PubMedCrossRefGoogle Scholar
  122. 122.
    Wollner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40.PubMedCrossRefGoogle Scholar
  123. 123.
    Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30(1):123–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Marinkovic SP, Gillen LM. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J. 2010;21(2):223–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Rademakers KL, Drossaerts JM, van Kerrebroeck PE, Oelke M, van Koeveringe GA. Prediction of sacral neuromodulation treatment success in men with impaired bladder emptying-time for a new diagnostic approach. Neurourol Urodyn. 2017;36(3):808–10.PubMedCrossRefGoogle Scholar
  126. 126.
    Reinberg Y, Fleming T, Gonzalez R. Renal rupture after the Crede maneuver. J Pediatr. 1994;124(2):279–81.PubMedCrossRefGoogle Scholar
  127. 127.
    Furusawa K, Tokuhiro A, Sugiyama H, Ikeda A, Tajima F, Genda E, et al. Incidence of symptomatic autonomic dysreflexia varies according to the bowel and bladder management techniques in patients with spinal cord injury. Spinal Cord. 2011;49(1):49–54.PubMedCrossRefGoogle Scholar
  128. 128.
    Barendrecht MM, Oelke M, Laguna MP, Michel MC. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99(4):749–52.PubMedCrossRefGoogle Scholar
  129. 129.
    Dasgupta R. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int. 2004;94(1):191–2.PubMedCrossRefGoogle Scholar
  130. 130.
    Hindley RG, Brierly RD, Thomas PJ. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int. 2004;93(1):89–92.PubMedCrossRefGoogle Scholar
  131. 131.
    Thorner DA, Blaivas JG, Tsui JF, Kashan MY, Weinberger JM, Weiss JP. Outcomes of reduction cystoplasty in men with impaired detrusor contractility. Urology. 2014;83(4):882–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Klarskov P, Holm-Bentzen M, Larsen S, Gerstenberg T, Hald T. Partial cystectomy for the myogenic decompensated bladder with excessive residual urine. Urodynamics, histology and 2-13 years follow-up. Scand J Urol Nephrol. 1988;22(4):251–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Hanna MK. New concept in bladder remodeling. Urology. 1982;19(1):6–12.PubMedCrossRefGoogle Scholar
  134. 134.
    von Heyden B, Anthony JP, Kaula N, Brock GB, Jakse G, Tanagho EA. The latissimus dorsi muscle for detrusor assistance: functional recovery after nerve division and repair. J Urol. 1994;151(4):1081–7.CrossRefGoogle Scholar
  135. 135.
    Stenzl A, Strasser H, Klima G, Eder I, Frauscher F, Klocker H, et al. Reconstruction of the lower urinary tract using autologous muscle transfer and cell seeding: current status and future perspectives. World J Urol. 2000;18(1):44–50.PubMedCrossRefGoogle Scholar
  136. 136.
    Ninkovic M, Stenzl A, Schwabegger A, Bartsch G, Prosser R, Ninkovic M. Free neurovascular transfer of latisstmus dorsi muscle for the treatment of bladder acontractility: II. Clinical results. J Urol. 2003;169(4):1379–83.PubMedCrossRefGoogle Scholar
  137. 137.
    Stoffel JT. Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127–35.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Klausner AP, Steers WD. The neurogenic bladder: an update with management strategies for primary care physicians. Med Clin North Am. 2011;95(1):111–20.PubMedCrossRefGoogle Scholar
  139. 139.
    Reynard JM, Vass J, Sullivan ME, Mamas M. Sphincterotomy and the treatment of detrusor-sphincter dyssynergia: current status, future prospects. Spinal Cord. 2003;41(1):1–11.PubMedCrossRefGoogle Scholar
  140. 140.
    Perrigot M, Delauche-Cavallier MC, Amarenco G, Geffriaud C, Stalla-Bourdillon A, Costa P. Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group. Neurourol Urodyn. 1996;15(2):119–31.PubMedCrossRefGoogle Scholar
  141. 141.
    Petersen T, Husted SE, Sidenius P. Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. Scand J Urol Nephrol. 1989;23(3):189–94.PubMedCrossRefGoogle Scholar
  142. 142.
    Moon KH, Park CH, Jung HC, Oh TH, Kim JS, Kim DY. A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder. Low Urin Tract Symptoms. 2015;7(1):27–31.PubMedCrossRefGoogle Scholar
  143. 143.
    Abrams P, Amarenco G, Bakke A, Buczyński A, Castro-Diaz D, Harrison S, European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group, et al. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol. 2003;170(4 Part 1):1242–51.PubMedCrossRefGoogle Scholar
  144. 144.
    Kakizaki H, Ameda K, Kobayashi S, Tanaka H, Shibata T, Koyanagi T. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol. 2003;10:576–81.PubMedCrossRefGoogle Scholar
  145. 145.
    Stankovich EIU, Borisov VV, Demina TL. Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis. Urologiia. 2004;4:48–51.Google Scholar
  146. 146.
    Swierzewski SJ 3rd, Gormley EA, Belville WD, Sweetser PM, Wan J, McGuire EJ. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol. 1994;151(4):951–4.PubMedCrossRefGoogle Scholar
  147. 147.
    Yasuda K, Yamanishi T, Kawabe K, Ohshima H, Morita T. The effect of urapidil on neurogenic bladder a placebo controlled double-blind study. J Urol. 1996;156(3):1125–30.PubMedCrossRefGoogle Scholar
  148. 148.
    Yamanishi T, Yasuda K, Homma Y, Kawabe K, Morita T. A multicenter placebo-controlled, double-blind trial of urapidil, an alpha-blocker, on neurogenic bladder dysfunction. Eur Urol. 1999;35(1):45–51.PubMedCrossRefGoogle Scholar
  149. 149.
    Krane RJ, Olsson CA. Phenoxybenzamine in neurogenic bladder dysfunction. II. Clinical considerations. J Urol. 1973;110(6):653–6.Google Scholar
  150. 150.
    Cameron AP. Medical management of neurogenic bladder with oral therapy. Transl Androl Urol. 2016;5(1):51–62.PubMedPubMedCentralGoogle Scholar
  151. 151.
    Karsenty G, Baazeem A, Elzayat E, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results. Can J Urol. 2006;13(2):3027–33. new 140PubMedGoogle Scholar
  152. 152.
    Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.PubMedCrossRefGoogle Scholar
  153. 153.
    Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155(3):1023–9.PubMedCrossRefGoogle Scholar
  154. 154.
    De Sèze M, Petit H, Gallien P, De Sèze MP, Joseph PA, Mazaux JM, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002;42(1):56–62.PubMedCrossRefGoogle Scholar
  155. 155.
    Chen SL, Bih LI, Huang YH, Tsai SJ, Lin TB, Kao YL. Effect of single botulinum toxin A injection to the external urethral sphincter for treating detrusor external sphincter dyssynergia in spinal cord injury. J Rehabil Med. 2008;40(9):744–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Utomo E, Groen J, Blok BF. Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev. 2014;5:CD004927.Google Scholar
  157. 157.
    Olsen AL, Benson JT, McClellan E. Urethral sphincter needle electromyography in women: comparison of periurethral and transvaginal approaches. Neurourol Urodyn. 1998;17(5):531–5.PubMedCrossRefGoogle Scholar
  158. 158.
    Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatry. 1997;63(4):474–6.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37–41.PubMedCrossRefGoogle Scholar
  160. 160.
    Kuo HC. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008;27(8):793–6.PubMedCrossRefGoogle Scholar
  161. 161.
    Ahmed HU, Shergill IS, Arya M, Shah PJ. Management of detrusor-external sphincter dyssynergia. Nat Clin Pract Urol. 2006;3(7):368–80.PubMedCrossRefGoogle Scholar
  162. 162.
    Corcos J, Ginsberg D. An overview of treatment alternatives for different types of neurogenic bladder dysfunction in adults. In: Corcos J, Ginsberg D, Karsenty G, editors. Textbook of the neurogenic bladder. 3rd ed. Boca Raton: CRC Press/Taylor & Francis; 2016. p. 685–95.Google Scholar
  163. 163.
    McNamara ER, Webster GD, Peterson AC. The UroLume stent revisited: the Duke experience. Urology. 2013;82(4):933–6.PubMedCrossRefGoogle Scholar
  164. 164.
    Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord. 2009;47(6):486–91.PubMedCrossRefGoogle Scholar
  165. 165.
    Chaabane W, Guillotreau J, Castel-Lacanal E, Abu-Anz S, De Boissezon X, Malavaud B, et al. Neurourol Urodyn. 2011;30(4):547–50.PubMedCrossRefGoogle Scholar
  166. 166.
    McCoin JL, Bhadra N, Brose SW, Gustafson KJ. Does patterned afferent stimulation of sacral dermatomes suppress urethral sphincter reflexes in individuals with spinal cord injury? Neurourol Urodyn. 2015;34(3):219–23.PubMedCrossRefGoogle Scholar
  167. 167.
    Barbalat Y, Rutman M. Detrusor-external sphincter dyssynergia: review of minimally invasive and endoscopic management. Urology. 2016;90:3–7.PubMedCrossRefGoogle Scholar
  168. 168.
    Perkash I. Transurethral sphincterotomy. J Urol. 2009;181(4):1539–40.PubMedCrossRefGoogle Scholar
  169. 169.
    Madersbacher H, Scott FB. Twelve o’clock sphincterotomy: technique, indications, results. (Abbreviated report). Urol Int. 1975;30(1):75–6.PubMedCrossRefGoogle Scholar
  170. 170.
    Kiviat MD. Transurethral sphincterotomy: relationship of site of incision to postoperative potency and delayed hemorrhage. J Urol. 1975;114(3):399–401.PubMedCrossRefGoogle Scholar
  171. 171.
    Chancellor MB, Rivas DA, Abdill CK, Karasick S, Ehrlich SM, Staas WE. Prospective comparison of external sphincter balloon dilatation and prosthesis placement with external sphincterotomy in spinal cord injured men. Arch Phys Med Rehabil. 1994;75(3):297–305.PubMedCrossRefGoogle Scholar
  172. 172.
    Yang CC, Mayo ME. External urethral sphincterotomy: long-term follow-up. Neurourol Urodyn. 1995;14(1):25–31.PubMedCrossRefGoogle Scholar
  173. 173.
    Juma S, Mostafavi M, Joseph A. Sphincterotomy: long-term complications and warning signs. Neurourol Urodyn. 1995;14(1):33–41.PubMedCrossRefGoogle Scholar
  174. 174.
    Perkash I. Contact laser sphincterotomy: further experience and longer follow-up. Spinal Cord. 1996;34(4):227–33.PubMedCrossRefGoogle Scholar
  175. 175.
    Rivas DA, Chancellor MB, Staas WE Jr, Gomella LG. Contact neodymium:yttrium-aluminum-garnet laser ablation of the external sphincter in spinal cord injured men with detrusor sphincter dyssynergia. Urology. 1995;45(6):1028–31.PubMedCrossRefGoogle Scholar
  176. 176.
    Yalla S, Sullivan M, Resnick N. Update on detrusor hyperactivity with impaired contractility. Curr Bladder Dysfunct Rep. 2007;2:191–6.CrossRefGoogle Scholar
  177. 177.
    Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med. 1989;320(1):1–7.PubMedCrossRefGoogle Scholar
  178. 178.
    Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore KN. Urge incontinence and impaired detrusor contractility in the elderly. Neurourol Urodyn. 2002;21(2):126–31.PubMedCrossRefGoogle Scholar
  179. 179.
    Taylor JA 3rd, Kuchel GA. Detrusor underactivity: clinical features and pathogenesis of an underdiagnosed geriatric condition. J Am Geriatr Soc. 2006;54(12):1920–32.PubMedCrossRefGoogle Scholar
  180. 180.
    Pfisterer MH, Griffiths DJ, Schaefer W, Resnick NM. The effect of age on lower urinary tract function: a study in women. J Am Geriatr Soc. 2006;54(3):405–12.PubMedCrossRefGoogle Scholar
  181. 181.
    Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw KT. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. Age Ageing. 2015;44(2):219–25.PubMedCrossRefGoogle Scholar
  183. 183.
    Hennessey DB, Hoag N, Gani J. Sacral neuromodulation for detrusor hyperactivity with impaired contractility. Neurourol Urodyn. 2017. doi: 10.1002/nau.23255.
  184. 184.
    Wang CC, Lee CL, Kuo HC. Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility. Toxins (Basel). 2016;8(3):82.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jacques Corcos
    • 1
  • Mikolaj Przydacz
    • 1
  1. 1.Department of UrologyJewish General Hospital, McGill UniversityMontrealCanada

Personalised recommendations